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Obstructive cardiac tumor in Hodgkin's lymphoma: course of cardiac
involvement under emergency chemotherapy
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Introduction: Cardiac involvement in Hodgkin’s disease (HD) is one of
the least investigated subjects in cardiac oncology. Emergency chemotherapy
is a rare necessity in Hodgkin’s disease, but life-threatening cardiac involve-
ment is possible, compromising hemodynamic stability. 
Cases report description: We report a case of Hodgkin's lymphoma which
presented with acute obstructive left heart failure. It is about a 37 years old
patient treated in 2000 for HD, type3, stage IVB medullar by chemotherapy
(4MOPP+ABVD) followed by radiotherapy, and judged in complete remis-
sion. Few months ago, the patient presents a cardiac relapse, echocardiography
revealed an enormous left atrial mass inducing a subtotal mitral obstruction
confirmed by the tomodensitomety. After a multidisciplinary concertation we
used the CEOP protocol (cyclophosphamide 650mg/m2, etoposid100 mg/m2,
oncovin 1,4mg/m2, prednisone, 40mg/m2) associated to the conventional heart
failure treatement. Under chemotherapy the evolution was favourable with
amelioration of symptoms strengthen by regression of cardiac mass gradually
in the weekly echocardiography checking after 4 cures.
Discussion: HD is not a steroid-sensitive disease, no single drug is rapidly
efficient, and no recommendation is available in the literature regarding urgent
cytoreduction. Therefore, if a decision for emergency chemotherapy is made,
an aggressive combination may be recommended. In addition, newer agents
resulting in improved cancer therapy outcomes might alter the prevalence and
location of metastatic deposits to include more unusual disease sites, including
intracardiac locations.
Conclusions/Implications: Lymphomatous involvement of the heart, pre-
viously a rarity, is now being reported with greater frequency. The increased
incidence might be partly a result of increased clinical awareness, improved
imaging techniques. Adaptative chemotherapy can successfully improve the
long term outcome of these patients. 
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Pericarditis is a common manifestation in Systemic Lupus Erythematosus
(SLE) that reveals the disease in 10-40% of the cases. This effusion is usually
a small one, non-compressive. The aim of our study was to determine the inci-
dence of pericarditis in SLE patients in our department and its characteristics. 
Patients and methods: We retrospectively reviewed the records of sixty
six patients (62 women and 4 men, 15 to 78 years of age) with a SLE followed
at our department since 2003. The diagnosis of SLE was established according
to criteria defined by the American Rheumatism Association
Results: All our patients with pericarditis were asymptomatic, except one
who presented a tamponade requiring surgical drainage. We divided our
patients in two groups: – G1: patients without pericarditis (16 patients) and
G2: patients with pericarditis (50 patients). There is no differences in age
(mean age 34±4 vs. 37±5 years, p<0.5) and sex (female predominance in the
2 groups). Patients with pericardial effusion are more likely to have pericardial
pain and active lupus, Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) is more higher but not significantly in G2 compared to G1 (11.6±8
vs 9.8±7, p=0.4.). The pleurisy was present in 14% of patients in G1 vs 25%
of patients in G2, p = 0.3. There is no difference in renal and neurological
affection between the two groups. Serologically, the production of antinuclear
antibodies and Antibodies to double-stranded DNA (anti-dsDNA is the most
important finding in both groups, respectively: 78% in G1 vs 87.5% in G2,
p=0.4 and 54% in G1 vs 62.5% in G2 p=0.6).There was no difference between
both groups in other antibodies: anti-SSA/Ro, anti-SSB/La antigen and anti-
phospholipid. All patients received corticosteroids with regression of peri-
carditis 
Conclusion: Pericarditis is the most studied cardiovascular manifestation
of SLE. Echocardiography represents the standard method to investigate peri-
cardial abnormalities and is able to demonstrate mild effusion or thickening of
pericardial layers, therefore, should be performed periodically in SLE patients. 
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Pulmonary hypertension (PHT) is one main cause of postoperative mor-
bidity and mortality after repair of CHD. Although efficacy of iNO is well-
established, the utilization of sildenafil is not yet clearly defined. The aim of
this study was to assess efficacy of sildenafil after CHD repair in children.
Methods: Retrospective analysis of patients who received sildenafil in
postoperative course after CHD repair, from 2005 to 2012. Duration of
mechanical ventilation, CICU and in-hospital stay, pulmonary pressure and
overall outcome were assessed. Patients were divided into group I (sildenafil
onset <H24) and II (> H24). 
Results: 50 patients were included: 30 in I and 20 in II. Mean age was
11.5mos, (med3.7mos), mean weight 4.4kg. CHD included 20VSD,
2VSD+coarctation, 9AVSD, 3truncus arteriosus, 2TGV, 3TOF, 9abnormal
pulmonary venous return, 3miscellaneous. Mechanical ventilation duration
was 8.4d, CICU stay 12.9d, hospital stay 21.6d. Bypass time was 100.8±
45mn, aortic clamp time 60.2±22mn. InhaledNO was administered within
5mn post-bypass, at 11.3±5.5ppm and duration of 4±3 days. Sildenafil dose
was 0.25-2mg/kg/4h, 1stdose was 0.67mg/kg/4h. Mean sildenafil dose was
1.16mg/kg/4h at time of iNO withdrawal. Duration of sildenafil was
22.4±14.6days. Preoperative systolic pulmonary pressure (PAPs) /systolic
aortic pressure (PAs) was 0.94±0.1. Preoperative PAPs decreased from 72 to
36.5mmhg at iNO cessation, PAPs/PAs from 0.94 to 0.43 and PAPmean/
PAmean from 0.8 to 0.46. PaO2/FiO2 increased from 121.4 at end-bypass to
269 at iNO cessation. Duration of ventilation was 6.2d vs 11.6d (p= 0.04),
CICU stay 9.4d vs 18d (p= 0.005), in-hospital stay 16d vs 30d (p= 0.001), in
groups I and II. Duration of iNO was shorter in I (3.3d) than II (5d), p=0.05.
Preoperative PAPs did not differ between the 2 groups. No significant side
effect occurred. Overall mortality was 4%; 4 patients needed long term silde-
nafil therapy. At latest evaluation, 38% were in NYHA class I, 40% NYHA II
and 22 NYHA III. 
Conclusion: Sildenafil is safe and reliable in postoperative course after
surgery for CHD in children and efficacy is optimal if administered < H24
after bypass. 
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